Legal Settlements and Loss Contingencies	6 Months Ended
Jun. 30, 2024
Legal Settlements and Loss Contingencies	NOTE 9 – Legal settlements and loss contingencies: In the second quarter of 2024, Teva recorded expenses of $83 million in legal settlements and loss contingencies, compared to $462 million in the second quarter of 2023. Expenses in the second quarter of 2024 were mainly related to an update to the estimated settlement provision for the opioid cases (mainly the effect of the passage of time on the net present value of the discounted payments), as well as an update in the estimated provision related to the settlement of several opt-out claims in connection with the Ontario Teachers Securities litigation, partially offset by an update to the estimated provision for the U.S. DOJ patient assistance program litigation. Expenses in the second quarter of 2023 were mainly related to a provision recorded in connection with the U.S. DOJ criminal antitrust charges on the marketing and pricing of certain Teva USA generic products, an update to the estimated settlement provision related to some of the remaining opioid cases including an agreement in principle on private hospital cases, and an update to the provision related to the settlement in the reverse-payment antitrust litigation over certain HIV medicines. See note 10. In the first six months of 2024, Teva recorded expenses of $188 million in legal settlements and loss contingencies, compared to $695 million in the first six months of 2023. Expenses in the first six months of 2024 were mainly related to an update to the estimated settlement provision for the opioid cases (mainly the effect of the passage of time on the net present value of the discounted payments), as well as an update in the estimated provision related to the settlement of several opt-out claims in connection with the Ontario Teachers Securities litigation. Expenses in the first six months of 2023 were mainly related to an update to the estimated settlement provision related to the remaining opioid cases, the provision relating to the U.S. DOJ criminal antitrust charges on the marketing and pricing of certain Teva USA generic products, an update to the estimated provision related to the U.S. DOJ patient assistance program litigation and the provision related to the settlement of the reverse-payment antitrust litigation over certain HIV medicines. As of June 30, 2024 and December 31, 2023, Teva’s provision for legal settlements and loss contingencies recorded under accrued expenses and other taxes and long-term liabilities was $4,730 million and $4,771 million, respectively.

Legal Settlements and Loss Contingencies

6 Months Ended

Jun. 30, 2024

Legal Settlements and Loss Contingencies

NOTE 9 – Legal settlements and loss contingencies:

In the second quarter of 2024, Teva recorded expenses of $83 million in legal settlements and loss contingencies, compared to $462

million in the second quarter of 2023. Expenses in the second quarter of 2024 were mainly related to an update to the estimated settlement provision for the opioid cases (mainly the effect of the passage of time on the net present value of the discounted payments), as well as an update in the estimated provision related to the settlement of several

opt-out

claims in connection with the Ontario Teachers Securities litigation, partially offset by an update to the estimated provision for the U.S. DOJ patient assistance program litigation. Expenses in the second quarter of 2023 were mainly related to a provision recorded in connection with the U.S. DOJ criminal antitrust charges on the marketing and pricing of certain Teva USA generic products, an update to the estimated settlement provision related to some of the remaining opioid cases including an agreement in principle on private hospital cases, and an update to the provision related to the settlement in the reverse-payment antitrust litigation over certain HIV medicines. See note 10.

In the first six months of 2024, Teva recorded expenses of $188 million in legal settlements and loss contingencies, compared to $695

million in the first six months of 2023. Expenses in the first six months of 2024 were mainly related to an update to the estimated settlement provision for the opioid cases (mainly the effect of the passage of time on the net present value of the discounted payments), as well as an update in the estimated provision related to the settlement of several

opt-out

claims in connection with the Ontario Teachers Securities litigation. Expenses in the first six months of 2023 were mainly related to an update to the estimated settlement provision related to the remaining opioid cases, the provision relating to the U.S. DOJ criminal antitrust charges on the marketing and pricing of certain Teva USA generic products, an update to the estimated provision related to the U.S. DOJ patient assistance program litigation and the provision related to the settlement of the reverse-payment antitrust litigation over certain HIV medicines.

of June 30, 2024 and December 31, 2023, Teva’s provision for legal settlements and loss contingencies recorded under accrued expenses and other taxes and long-term liabilities was $4,730 million and $4,771 million, respectively.